Ligand Pharmaceuticals Incorporated LGNYZ Company

New Post Public Reply Private Reply Replies (0) Message Board

Sep 14, 2013 at 4:31 PM

Ligand Pharmaceuticals Incorporated LGNYZ Company Overview

Stock Message Board http://investorshangout.com/search?q=LGNYZ&am...mp;yt1=Go!

Ligand Pharmaceuticals Incorporated LGNYZ Current Price and Quotes
Last Price 0.036
Previous Close 0.036 Open 0.036
Daily Range 0.036 - 0.036 52wk Range 0.05 - 0.0001
Volume 1,750 Dividend 0.000182
Average Vol (3m) 4,486 Yield 0.505556
Ligand Pharmaceuticals Incorporated LGNYZ
Company Information

11119 North Torrey Pines Road
Suite 200
La Jolla, CA 92037

Website: http://www.ligand.com
Phone: 858-550-7500

Ligand Pharmaceuticals Incorporated LGNYZ
Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.

Ligand Pharmaceuticals Incorporated LGNYZ
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Not Available
Latest Report Jun 30, 2013 10-Q
CIK 0000886163
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 1987
Employees 550 a/o Dec 31, 2004
Company Officers/Contacts

David E. Robinson President, CEO
Paul V. Maier CFO
Matthew W. Foehr EVP, COO
Charles S. Berkman Vice President, Secretary, General Counsel
Erika Luib IR
Company Directors

David E. Robinson Chairman
John LaMattina
Sunil Patel
Service Providers

Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available

Ligand Pharmaceuticals Incorporated LGNYZ
LGNYZ Security Details Other Company Securities

Share Structure

Market Value1 Not Available
Shares Outstanding Not Available
Float Not Available
Authorized Shares Not Available
Par Value No Par Value
Shareholders

Shareholders of Record Not Available
Corporate Actions

Ex. Date Record Date Pay Date
Dividend (0.00018) Jan 16, 2013 Dec 27, 2012 Jan 01, 2013
Dividend (0.0035) Jan 12, 2012 Dec 28, 2011 Jan 02, 2012
Short Selling Data

Short Interest 0 (-100%)
Aug 30, 2013
Significant Failures to Deliver No
Transfer Agent(s)

Ligand Pharmaceuticals Incorporated LGNYZ Recent News

Sept 5, 2013 OTC Signal Daily Stock Watch - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
Aug 14, 2013 Ligand Enters Global License Agreement with CURx Pharmaceuticals, Inc. for Captisol-Enabled(TM) Topiramate Injection
Aug 1, 2013 Ligand Reports Second Quarter Financial Results
Jul 29, 2013 New License Agreements and Financial Results Release - Research Report on Elan, Waters, InterMune, Spectranetics, and Ligand
Jul 26, 2013 Ligand Partner GlaxoSmithKline Receives Positive CHMP Opinion for REVOLADE(TM) in Thrombocytopenia Associated with Chronic Hepatitis C Infection
Jul 26, 2013 Ligand Receives Orphan Designation for Captisol-Enabled(TM) Topiramate Injection
Jul 24, 2013 Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene
Jul 22, 2013 Ligand Signs Global License Agreement with Azure for Lasofoxifene
Jul 17, 2013 Ligand to Report Second Quarter Results on August 1st
Jun 24, 2013 Ligand Announces Positive Preclinical Data for Glucagon Program in Model of Type 1 Diabetes

1
2
next >

Ligand Pharmaceuticals Incorporated LGNYZ Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Total Revenue 31,388 30,037 23,538 38,940
Cost of Revenue 3,601 4,909 - -
Gross Profit 27,787 25,128 23,538 38,940
Operating Expenses

Research and Development 10,790 10,291 22,067 39,870
Sales, General and Admin. 16,108 13,275 11,127 (6,640)
Non-Recurring Items 315 2,260 19,648 15,677
Other - - - -
Operating Income 574 (698) (29,304) (9,967)
Income From Continuing Operations

Add'l Income/Expense Items (1,134) (383) 13,519 365
Earnings Before Interest and Tax (3,865) (3,558) (15,403) (9,602)
Interest Expense - - - 270
Earnings Before Tax (3,865) (3,558) (15,403) (9,872)
Income Tax (1,191) (13,270) (2,617) (1,535)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (2,674) 9,712 (12,786) (8,337)
Non Recurring Events

Discontinued Operations 2,147 3 2,413 6,389
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (527) 9,715 (10,373) (1,948)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (527) 9,715 (10,373) (1,948)

LGNYZ Ligand Pharmaceuticals Incorporated Research DD Guide

LGNYZ Ligand Pharmaceuticals Incorporated Stock Message Board http://investorshangout.com/search?q=LGNYZ&am...mp;yt0=Go!
LGNYZ Ligand Pharmaceuticals Incorporated Stock Quote http://www.otcmarkets.com/stock/LGNYZ/quote
LGNYZ Ligand Pharmaceuticals Incorporated Stock Chart http://www.otcmarkets.com/stock/LGNYZ/chart
LGNYZ Ligand Pharmaceuticals Incorporated Company Info http://www.otcmarkets.com/stock/LGNYZ/company-info
LGNYZ Ligand Pharmaceuticals Incorporated Recent News http://www.otcmarkets.com/stock/LGNYZ/news
LGNYZ Ligand Pharmaceuticals Incorporated Financials http://www.otcmarkets.com/stock/LGNYZ/financials
LGNYZ Ligand Pharmaceuticals Incorporated Filings and Disclosure http://www.otcmarkets.com/stock/LGNYZ/filings
LGNYZ Ligand Pharmaceuticals Incorporated Short Sales http://www.otcmarkets.com/stock/LGNYZ/short-sales
LGNYZ Ligand Pharmaceuticals Incorporated Insider Disclosure http://www.otcmarkets.com/stock/LGNYZ/insider-transactions
LGNYZ Ligand Pharmaceuticals Incorporated Research Reports http://www.otcmarkets.com/stock/LGNYZ/research
LGNYZ Ligand Pharmaceuticals Incorporated Summary http://finance.yahoo.com/q?s=LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated Historical Prices http://finance.yahoo.com/q/hp?s=LGNYZ+Historical+Prices
LGNYZ Ligand Pharmaceuticals Incorporated Interactive Chart http://finance.yahoo.com/echarts?s=LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated Basic Chart http://finance.yahoo.com/q/bc?s=LGNYZ+Basic+Chart
LGNYZ Ligand Pharmaceuticals Incorporated Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=LGNYZ+Basic+Tech.+Analysis
LGNYZ Ligand Pharmaceuticals Incorporated Headlines http://finance.yahoo.com/q/h?s=LGNYZ+Headlines
LGNYZ Ligand Pharmaceuticals Incorporated Press Releases http://finance.yahoo.com/q/p?s=LGNYZ+Press+Releases
LGNYZ Ligand Pharmaceuticals Incorporated Company Profile http://finance.yahoo.com/q/pr?s=LGNYZ+Profile
LGNYZ Ligand Pharmaceuticals Incorporated Key Statistics http://finance.yahoo.com/q/ks?s=LGNYZ+Key+Statistics
LGNYZ Ligand Pharmaceuticals Incorporated Industry http://finance.yahoo.com/q/in?s=LGNYZ+Industry
LGNYZ Ligand Pharmaceuticals Incorporated Major Holders http://finance.yahoo.com/q/mh?s=LGNYZ+Major+Holders
LGNYZ Ligand Pharmaceuticals Incorporated Insider Transactions http://finance.yahoo.com/q/it?s=LGNYZ+Insider+Transactions
LGNYZ Ligand Pharmaceuticals Incorporated Insider Roster http://finance.yahoo.com/q/ir?s=LGNYZ+Insider+Roster
LGNYZ Ligand Pharmaceuticals Incorporated Income Statement http://finance.yahoo.com/q/is?s=LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated Balance Sheet http://finance.yahoo.com/q/bs?s=LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated Cash Flow http://finance.yahoo.com/q/cf?s=LGNYZ+Cash+Flow&annual
LGNYZ Ligand Pharmaceuticals Incorporated Nasdaq http://www.nasdaq.com/symbol/LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated Market Watch http://www.marketwatch.com/investing/stock/LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated Bloomberg http://www.bloomberg.com/quote/LGNYZ:US
LGNYZ Ligand Pharmaceuticals Incorporated Morningstar http://quotes.morningstar.com/stock/s?t=LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated Bussinessweek http://investing.businessweek.com/research/st...cker=LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated Barchart http://www.barchart.com/quotes/stocks/LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated OTC Short Report http://otcshortreport.com/index.php?index=LGNYZ
LGNYZ Ligand Pharmaceuticals Incorporated Investopedia http://www.investopedia.com/markets/stocks/LGNYZ/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....